MX394216B - Abx196 para usarse en el tratamiento del cáncer de vejiga. - Google Patents

Abx196 para usarse en el tratamiento del cáncer de vejiga.

Info

Publication number
MX394216B
MX394216B MX2020002812A MX2020002812A MX394216B MX 394216 B MX394216 B MX 394216B MX 2020002812 A MX2020002812 A MX 2020002812A MX 2020002812 A MX2020002812 A MX 2020002812A MX 394216 B MX394216 B MX 394216B
Authority
MX
Mexico
Prior art keywords
treatment
bladder cancer
abx196
pharmaceutical compositions
relates
Prior art date
Application number
MX2020002812A
Other languages
English (en)
Spanish (es)
Other versions
MX2020002812A (es
Inventor
Didier Scherrer
Hartmut Ehrlich
Philippe Pouletty
Sandrine Crabe
Original Assignee
Abivax
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abivax filed Critical Abivax
Publication of MX2020002812A publication Critical patent/MX2020002812A/es
Publication of MX394216B publication Critical patent/MX394216B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX2020002812A 2017-09-13 2018-09-13 Abx196 para usarse en el tratamiento del cáncer de vejiga. MX394216B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17306182 2017-09-13
PCT/EP2018/074778 WO2019053142A1 (en) 2017-09-13 2018-09-13 ABX196 FOR USE IN THE TREATMENT OF BLADDER CANCER

Publications (2)

Publication Number Publication Date
MX2020002812A MX2020002812A (es) 2020-07-21
MX394216B true MX394216B (es) 2025-03-24

Family

ID=60001797

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020002812A MX394216B (es) 2017-09-13 2018-09-13 Abx196 para usarse en el tratamiento del cáncer de vejiga.

Country Status (18)

Country Link
US (1) US11266667B2 (https=)
EP (1) EP3681512B1 (https=)
JP (1) JP7214718B2 (https=)
KR (1) KR102706165B1 (https=)
CN (1) CN111182907B (https=)
AU (1) AU2018332046B2 (https=)
BR (1) BR112020004778A2 (https=)
CA (1) CA3075443A1 (https=)
CU (1) CU20200020A7 (https=)
DK (1) DK3681512T3 (https=)
ES (1) ES2893549T3 (https=)
HR (1) HRP20211351T1 (https=)
IL (1) IL273054B2 (https=)
MX (1) MX394216B (https=)
PL (1) PL3681512T3 (https=)
PT (1) PT3681512T (https=)
WO (1) WO2019053142A1 (https=)
ZA (1) ZA202001435B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117222414A (zh) 2021-03-01 2023-12-12 脱落性治疗公司 用于激活恒定自然杀伤t-细胞的化合物和用于消除炎性衰老细胞的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8207135B2 (en) * 2007-12-05 2012-06-26 Wittycell Compositions for and methods of enhancing the immune response to antigens
JP5809560B2 (ja) * 2008-10-08 2015-11-11 アビヴァックス インフルエンザに対して使用するためのワクチン組成物
HK1197068A1 (en) * 2011-01-05 2015-01-02 台湾大学 Methods for preparation of glycosphingolipids and uses thereof
BR112019004906A2 (pt) 2016-09-14 2019-06-25 Abivax combinação incluindo abx196 para o tratamento de câncer

Also Published As

Publication number Publication date
US20200230163A1 (en) 2020-07-23
RU2020109889A3 (https=) 2022-01-28
AU2018332046A1 (en) 2020-03-19
HRP20211351T1 (hr) 2021-11-26
JP2020533368A (ja) 2020-11-19
EP3681512B1 (en) 2021-08-04
CN111182907A (zh) 2020-05-19
ES2893549T3 (es) 2022-02-09
CA3075443A1 (en) 2019-03-21
CN111182907B (zh) 2023-01-06
WO2019053142A1 (en) 2019-03-21
US11266667B2 (en) 2022-03-08
EP3681512A1 (en) 2020-07-22
AU2018332046B2 (en) 2024-06-13
ZA202001435B (en) 2022-07-27
PL3681512T3 (pl) 2022-01-17
MX2020002812A (es) 2020-07-21
IL273054B1 (en) 2023-01-01
BR112020004778A2 (pt) 2020-10-13
JP7214718B2 (ja) 2023-01-30
KR20200102412A (ko) 2020-08-31
CU20200020A7 (es) 2020-11-30
DK3681512T3 (da) 2021-09-06
KR102706165B1 (ko) 2024-09-13
RU2020109889A (ru) 2021-09-06
PT3681512T (pt) 2021-10-06
IL273054A (en) 2020-04-30
IL273054B2 (en) 2023-05-01

Similar Documents

Publication Publication Date Title
CL2019002304A1 (es) Compuestos para el tratamiento del cáncer.
ECSP19015192A (es) Composiciones y métodos de inhibir masp-3 para el tratamiento de diversas enfermedades y trastornos
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
MX2021006531A (es) Composicion que contiene arn para tratamiento de enfermedades tumorales.
MX2020011104A (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
DOP2019000005A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
CL2016001609A1 (es) Composiciones farmacéuticas que comprenden azd9291.
CO2017013443A2 (es) Composiciones que comprenden cepas bacterianas del género blautia
CR20150316A (es) Compuestos y sus métodos de empleo
MX394062B (es) Métodos para el tratamiento del cáncer ovárico.
MX2017001279A (es) Usos y composiciones de la flagelina.
UY35916A (es) Compuestos tricíclicos como agentes antineoplásicos inhibidores del bromodominio
SV2018005687A (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer
CL2015002571A1 (es) Composiciones y métodos para le diagnostico y tratamiento del cáncer hepático.
MX369041B (es) Proteinas quimericas tipo fosfatasa alcalina.
CU20190101A7 (es) Imidazopirimidinas diazabicíclicas sustituidas
MX2018010993A (es) Derivados de icariina e icaritina.
DOP2017000049A (es) Compuestos tricíclicos que contienen nitrógeno para el tratamiento de la infección por neisseria gonorrhoeae
MX395231B (es) Compuestos eficaces en el tratamiento de la hepatotoxicidad y enfermedades de hígado graso, y uso de los mismos.
CL2017002170A1 (es) Desacetoxitubulisina h y análogos de esta.
MX2023012640A (es) Uso de profarmacos de riluzol para tratar ataxias.
MX386860B (es) Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cáncer.
MX2017001352A (es) Derivados de pirrolidinona como inhibidores de metionina aminopeptidasa 2 (metap-2).
MX2022014792A (es) Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican.